Study of INCB086550 in Select Solid Tumors

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 2, 2021

Primary Completion Date

March 26, 2024

Study Completion Date

March 26, 2024

Conditions
Non Small Cell Lung CancerUrothelial CancerRenal Cell CarcinomaHepatocellular CarcinomaMelanoma
Interventions
DRUG

INCB086550

INCB086550 will be administered orally twice a day.

Trial Locations (20)

1085

Semmelweis Egyetem, Budapest

4004

Complex Onclogy Center Plovdiv Eood, Plovdiv

5300

"Multiprofile Hospital For Active Treatment Dr. Tota Venkova Jsc", Gabrovo

6000

Bacs Kiskun Megyei Oktatokorhaz, Kecskemét

8000

Complex Oncology Center - Burgas Eood, Burgas

8582

Complex Oncology Center - Burgas Eood, Farkasgyepű

9000

Shatod Dr. Marko - Varna Ltd, Varna

16427

The Catholic University of Korea St. Vincent'S Hospital, Gyeonggi-do

16499

Ajou University Hospital, Suwon

33305

Chang Gung Memorial Hospital Linkou, Taoyuan

40022

Rmi Sumy Regional Clinical Oncology Dispensary, Sumy

43018

Volyn Regional Oncological Dispensary, Lutsk

49102

Multifield Clinical Hospital No 4, Dnipro

50048

Mi Kryviy Rih Center of Dnipropetrovsk Regional Council, Kryvyi Rih

61166

Ci of Healthcare Regional Clinical Specialized Dispensary of the Radiation Protection, Kharkiv

88000

Cne Ccch of Uzh Cc Oncological Center, Uzhhorod

02841

Korea University Anam Hospital, Seoul

03722

Severance Hospital Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

07352

Medical Clinic Innovacia Llc, Vyshhorod

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT04629339 - Study of INCB086550 in Select Solid Tumors | Biotech Hunter | Biotech Hunter